Given how widely open-source components are used in commercial codebases, few organizations can assume they are insulated from this risk.​ And according to Sergej Epp of security platform Sysdig, the ...
Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results